Cover Image

TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Adam Nasim, David Fairman, Emma Nixon, Prabhas Jagdale, Zhiyi Cui, Krithika Mohan, James W.T. Yates
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
by: KyoungSoo Lim, et al.
Published: (2024)

Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross‐Sectional Study
by: Ting Zhu, et al.
Published: (2026)

Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
by: Miramar Sami Kardouh, et al.
Published: (2025)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
by: Peiying Zuo, et al.
Published: (2024)

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
by: Yu Wu, et al.
Published: (2025)

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates
by: Andrew B. SyBing, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
by: Chang Liu, et al.
Published: (2026)

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
by: Robin Thomas Ulrich Haid, et al.
Published: (2024)

Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins
by: Xiaofan Tian, et al.
Published: (2024)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
by: Sébastien Taillemite, et al.
Published: (2026)

Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still Out
by: Mohamed G. Shiha, et al.
Published: (2025)

Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®
by: Roberta Noseda, et al.
Published: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
by: Jian Wang, et al.
Published: (2024)

Establishment of a Biomarker‐Directed Clinical Endpoint Model for Early‐Stage Parkinson's Disease Patients
by: Churni Gupta, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
by: John D. Davis, et al.
Published: (2024)

Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
by: Asma El‐Zailik, et al.
Published: (2024)

Biopsy‐Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment
by: Stiliano Maimaris, et al.
Published: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
by: Mengmeng Lin, et al.
Published: (2025)

Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply
by: Stiliano Maimaris, et al.
Published: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
by: David Mehdi Asgher Niazi, et al.
Published: (2026)

Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
by: Victor Mirleau, et al.
Published: (2025)

A Reflection on the Evolution of Antibody‐Based Therapies in Oncology: Trastuzumab as an Exemplar—Commentary on Dijkers et al.
by: Sarah A. Holstein
Published: (2025)

Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL
by: Candice Jamois, et al.
Published: (2025)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
by: Xiaoyu Men, et al.
Published: (2024)

Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
by: Prathap Nagaraja Shastri, et al.
Published: (2024)

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
by: Sara Belli, et al.
Published: (2024)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
by: Irina Kareva, et al.
Published: (2025)

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study
by: Saqr Alsakarneh, et al.
Published: (2025)

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial
by: Dave Singh, et al.
Published: (2025)

Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
by: Thomas M. Polasek, et al.
Published: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
by: Christophe Corpechot
Published: (2026)

Editorial: Targeting Urgency in IBD —A Historical Divide
by: Daniele Noviello, et al.
Published: (2025)

Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine
by: Jie En Valerie Sia, et al.
Published: (2024)

Does Changing the Context of Use Change the Value Proposition of CiPA ?
by: Charles T. Benson, et al.
Published: (2026)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis
by: Enzo Emanuele, et al.
Published: (2025)

Liberty on Odaiba, Against the Silhouette of Tokyo Bay: Inspirations for Moving Hypothesis‐Generating Research to Patient‐Centered Therapeutics
by: Karthik Venkatakrishnan
Published: (2026)

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data
by: Kaisa Litonius, et al.
Published: (2024)

The Future of Machine Learning Within Target Identification: Causality, Reversibility, and Druggability
by: Jake P. Taylor‐King, et al.
Published: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)